

Heavy Metal Poisoning - Drugs In Development, 2021

<https://marketpublishers.com/r/HCA0424C387FEN.html>

Date: July 2021

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: HCA0424C387FEN

Abstracts

Heavy Metal Poisoning - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Drugs In Development, 2021, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II,

IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).

The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Heavy Metal Poisoning - Overview

Heavy Metal Poisoning - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Heavy Metal Poisoning - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heavy Metal Poisoning - Companies Involved in Therapeutics Development

Capture Pharmaceuticals Inc

EmeraMed Ltd

Medesis Pharma SA

PDX Pharmaceuticals LLC

ZoneOne Pharma Inc

Heavy Metal Poisoning - Drug Profiles

C-2E2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deferoxamine mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emeramide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDX-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Heavy Metal Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heavy Metal Poisoning - Dormant Projects

Heavy Metal Poisoning - Discontinued Products

Heavy Metal Poisoning - Product Development Milestones

Featured News & Press Releases

Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium

Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Heavy Metal Poisoning, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Heavy Metal Poisoning - Pipeline by Capture Pharmaceuticals Inc, 2021
Heavy Metal Poisoning - Pipeline by EmeraMed Ltd, 2021
Heavy Metal Poisoning - Pipeline by Medesis Pharma SA, 2021
Heavy Metal Poisoning - Pipeline by PDX Pharmaceuticals LLC, 2021
Heavy Metal Poisoning - Pipeline by ZoneOne Pharma Inc, 2021
Heavy Metal Poisoning - Dormant Projects, 2021
Heavy Metal Poisoning - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Heavy Metal Poisoning, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Heavy Metal Poisoning - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/HCA0424C387FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HCA0424C387FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970